The Committee discusses and makes recommendations on the safety and effectiveness of Pfizer’s Biologics License Application (BLA) 125769 (STN 125769/0), ABRYSVO for active immunization for the prevention of acute respiratory disease and lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in adults 60 years of age and older in a virtual meeting to be held on February 28 at 8:30 am. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PFE:
- Pfizer (NYSE:PFE) Could Buy Seagen to Bolster Oncology Portfolio
- Pfizer treatment of pulmonary arterial hypertension gets FDA orphan designation
- Pfizer’s elranatamab receives FDA and EMA filing acceptance
- Pfizer: FDA accepts for review BLA for RSV vaccine candidate
- Pfizer announces TALZENNA, XTANDI combination data from TALAPRO-2 study